Zhen Li, ADARx Pharmaceuticals CEO

A new play­er joins the RNA edit­ing race on the heels of Eli Lil­ly's $1B-plus deal

A day af­ter Eli Lil­ly inked a $1 bil­lion-plus deal to part­ner with a qui­et RNA edit­ing start­up, a new play­er has emerged to turn up the vol­ume.

ADARx Phar­ma­ceu­ti­cals un­cloaked on Thurs­day with a $75 mil­lion Se­ries B round to ush­er its RNA pro­grams in­to the clin­ic. The San Diego-based biotech was found­ed in 2019 to dis­cov­er ther­a­pies that pre­cise­ly tar­get and ed­it sin­gle-point mu­ta­tions on RNA tran­scripts.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.